Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). Forero-Torres, A., Moskowitz, C., Advani, R. H., Shah, B. D., Kostic, A., Albertson, T. M., Sandalic, L., Zhao, B., Fanale, M. A. AMER SOC CLINICAL ONCOLOGY. 2014

View details for DOI 10.1200/jco.2014.32.15_suppl.8505

View details for Web of Science ID 000358613204186